MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status

Planta Medica

Volumn 77, Issue 1, 2011, Pages 27-31

  Li, Wei ^a,b   Liu, Yong ^a   Li, Xue Xia ^c   Yu, Yang ^a   Wu, Jing Jing ^a   Wang, Qing ^d   Huo, Hong ^a   Wang, Li Ming ^e   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN UNIVERSITY   (China)

^d DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^e DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Celastraceae; mitogen activated protein kinases (MAPKs); p53; prostate cancer; Tripterygium wilfordii; triptolide

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOXANTRONE; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRIPTOLIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; CYTOSTATIC AGENTS; DITERPENES; EPOXY COMPOUNDS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHENANTHRENES; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

CELASTRACEAE; TRIPTERYGIUM WILFORDII;

EID: 78650055621     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1250076     Document Type: Article

References (32)

1. Kiviharju T M., Lecane P S., Sellers R G., Peehl D M. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002 8 2666-2674
2. Zhang R, Zhang P Y., Guo J, Yang D, Wang W J., Zheng M H., Ma Y C. Effects of triptolide on prostate carcinoma in mouse RM-1 cells. Zhonghua Nan Ke Xue 2007 13 237-241
3. Fidler J M., Li K, Chung C, Wei K, Ross J A., Gao M, Rosen G D. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003 2 855-862
4. Wang J, Waxman J. Chemotherapy for prostate cancer. Urol Oncol 2000 5 93-96
5. Heidenberg H B., Bauer J J., McLeod D G., Moul J W., Srivastava S. The role of the p 53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996 48 971-979 (Pubitemid 127739005)
6. Igney F H., Krammer P H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002 2 277-288
7. Dong J T. Prevalent mutations in prostate cancer. J Cell Biochem 2006 97 433-447
8. Navone N M., Troncoso P, Pisters L L., Goodrow T L., Palmer J L., Nichols W W., von Eschenbach A C., Conti C J. p 53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993 85 1657-1669
9. Jane E P., Premkumar D R., Pollack I F. AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p 53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. Cancer Lett 2007 257 36-46
10. Jiang X H., Wong B C. Y., Lin M C. M., Zhu G H., Kung H F., Jiang S H., Yang D, Lam S K. Functional p 53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappa B activation in gastric cancer cells. Oncogene 2001 20 8009-8018
11. Wan C K., Wang C, Cheung H Y., Yang M, Fong W F. Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p 53-deficient HL-60 cells. Cancer Lett 2006 241 31-41
12. Yang S, Chen J, Guo Z, Xu X M., Wang L, Pei X F., Yang J, Underhill C B., Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003 2 65-72
13. Watson J L., Greenshields A, Hill R, Hilchie A, Lee P W., Giacomantonio C A., Hoskin D W. Curcumin-induced apoptosis in ovarian carcinoma cells is p 53-independent and involves p 38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 2010 49 13-24
14. McCubrey J A., Steelman L S., Chappell W H., Abrams S L., Wong E W., Chang F, Lehmann B, Terrian D M., Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli A M., Franklin R A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007 1773 1263-1284
15. Arnoldussen Y J., Saatcioglu F. Dual specificity phosphatases in prostate cancer. Mol Cell Endocrinol 2009 309 1-7
16. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p 53 mediated p 38alpha MAPK activation through ROS generation. Apoptosis 2007 12 1733-1742
17. Wu G S. The functional interactions between the p 53 and MAPK signaling pathways. Cancer Biol Ther 2004 3 156-161
18. Vivar O I., Lin C L., Firestone G L., Bjeldanes L F. 3,3-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p 53 status. Biochem Pharmacol 2009 78 469-476
19. Chang H C., Huang C C., Huang C J., Cheng J S., Liu S I., Tsai J Y., Chang H T., Huang J K., Chou C T., Jan C R. Desipramine-induced apoptosis in human PC3 prostate cancer cells: activation of JNK kinase and caspase-3 pathways and a protective role of [Ca2+]i elevation. Toxicology 2008 250 9-14
20. Liu Q, Chen T, Chen H, Zhang M, Li N, Lu Z, Ma P, Cao X. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p 38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun 2004 319 980-986
21. Keepers Y P., Pizao P E., Peters G J., van Ark-Otte J, Winograd B, Pinedo H M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991 27 897-900
22. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns E S. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol 2006 175 1926-1931
23. Hsiao C J., Li T K., Chan Y L., Hsin L W., Liao C H., Lee C H., Lyu P C., Guh J H. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Biochem Pharmacol 2008 75 847-856
24. Carroll A G., Voeller H J., Sugars L, Gelmann E P. p 53 Oncogene mutations in three human prostate cancer cell lines. Prostate 1993 23 123-134
25. Girinsky T, Koumenis C, Graeber T G., Peehl D M., Giaccia A J. Attenuated response of p 53 and p 21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995 55 3726-3731
26. Chang W T., Kang J J., Lee K Y., Wei K, Anderson E, Gotmare S, Ross J A., Rosen G D. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p 53 pathway. J Biol Chem 2001 276 2221-2227
27. Papatsoris A G., Karamouzis M V., Papavassiliou A G. The power and promise of rewiring the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther 2007 6 811-819
28. Wagner E F., Nebreda A R. Signal integration by JNK and p 38 MAPK pathways in cancer development. Nat Rev Cancer 2009 9 537-549
29. Joo S S., Yoo Y M. Melatonin induces apoptotic death in LNCaP cells via p 38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009 47 8-14
30. Zhang Y X., Kong C Z., Wang H Q., Wang L H., Xu C L., Sun Y H. Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. Biochimie 2009 91 1173-1179
31. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung Y G., Chang C, Hopp T, Fuqua S A. W., Jaffray E, Hay R T., Palvimo J J., Jänne O A., Pestell R G. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 2002 22 3373-3388
32. Abreu-Martin M T., Chari A, Palladino A A., Craft N A., Sawyers C L. Mitogen-activated protein kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999 19 5143-5154